Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFudan University
About this trial
This study is an open-label, multi-cohort real-world research that explores the efficacy and safety of different second-line treatment regimens for gastric/gastroesophageal junction adenocarcinoma that has failed first-line fluoropyrimidine, platinum-based chemotherapy combined with immunotherapy.
Eligibility criteria
Qualifiers
Fully understand this study and voluntarily sign the informed consent form;
Between 18 and 80 years old (inclusive), male or female;
Patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma confirmed by pathology or histology;
ECOG performance status 0-2;
Disqualifiers
Patients with other malignancies within 5 years before enrollment, except for skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;
Patients who have received allogeneic bone marrow transplantation or organ transplantation in the past;
Patients with severe cardiovascular diseases within 6 months before enrollment, including unstable angina or myocardial infarction;
Patients allergic to the study drug or any of its auxiliary preparations;
Trial design
Treatments tested in this trial
- Albumin-bound Paclitaxel
- Immune Checkpoint Inhibitor
- Anti-angiogenic drug
- Trastuzumab emtansine
Treatment groups
250 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov